FluoGuide (FLOU) Investing in Life Science 2026 summary

Market opportunity and technology

• Cancer recurrence after surgery is a major problem, addressed by a drug that lights up cancer during surgery.

• The solution targets uPAR, an enzyme highly expressed in aggressive cancers, enabling visualization.

• Market potential is significant, with 45 million cancer procedures projected in 2030.

Clinical validation and regulatory progress

• Clinical trials have been conducted, and FDA granted Fast Track designation for high-grade glioma.

• Partnerships with major med tech companies are in place to facilitate market penetration.

• The drug is administered pre-surgery, binds to cancer, and enables real-time visualization during operations.

Focus areas and clinical endpoints

• Focus is on brain tumors (especially high-grade glioma) and head and neck cancers.

• The technology helps surgeons distinguish cancer from normal tissue, reducing unnecessary removal.

• Primary clinical endpoint is removal of contrast-enhancing tumor; secondary endpoint is removal of infiltrative cancer.